Iron Deficiency During First-line Chemotherapy in Metastatic Cancers: a Prospective Epidemiological Study

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2019 Jul 7

PMID 31278463

Citations 6

Authors

Angelique Saint

J Viotti

D Borchiellini

B Hoch

V Raimondi

C Hebert

R Largillier

L Evesque

P Follana

J M Ferrero

C Delaby

R Schiappa

E Chamorey

J Barriere

Affiliations

Soon will be listed here.

Abstract

Purpose: Anemia is common in oncology and negatively impacts quality of life. However, there is lack of knowledge about iron deficiency (ID) epidemiology. The aim of this study was to prospectively assess iron status in patients with locally advanced or metastatic cancer beginning chemotherapy.

Methods: In this prospective, multicenter cohort study, anemia and ID were evaluated in patients with locally advanced or metastatic solid tumors and lymphoma before starting chemotherapy. Blood samples were collected at inclusion (W0), 6 weeks (W6), and 12 weeks (W12). Prevalence was evaluated in the general population, according to tumor location and was correlated with tumor response.

Results: One hundred twenty-nine patients were enrolled between 2013 and 2015; 119 had solid tumors and 10 lymphomas. At W0, there were no significant difference between locations with a prevalence around 50-60% (range 47.2-70.4%) and only a trend for colorectal cancer (70.4%, P = 0.069) due to a higher prevalence of absolute ID (18.5%). Prevalence of ID+ decreased between W0 and W6 and remained stable until W12 due to the proportion of patients with ID and without anemia. However, anemia prevalence increased during W0 and W6 and remained stable to W6 from W12 due to patients with anemia but without ID. A significant correlation between tumor response and ID prevalence was found (P = 0.036).

Conclusions: We confirm the high prevalence of ID and anemia in cancer patients. ID status is correlated to tumor response providing a strong rationale for iron monitoring during cancer management.

Citing Articles

Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure.

Stevic I, Jankovic S, Georgiev A, Marinkovic V, Lakic D Sci Rep. 2024; 14(1):9074.

PMID: 38643204 PMC: 11032331. DOI: 10.1038/s41598-024-59710-3.

Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches.

Bozzini C, Busti F, Marchi G, Vianello A, Cerchione C, Martinelli G Front Oncol. 2024; 14:1380358.

PMID: 38628673 PMC: 11018927. DOI: 10.3389/fonc.2024.1380358.

Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer.

Yang Y, Li Y, Chen Z BMC Cancer. 2023; 23(1):1095.

PMID: 37950201 PMC: 10638799. DOI: 10.1186/s12885-023-11620-9.

How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome.

Rohr M, Brandenburg V, Brunner-La Rocca H Eur J Med Res. 2023; 28(1):15.

PMID: 36617559 PMC: 9827648. DOI: 10.1186/s40001-022-00922-6.

Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?.

Mehedinti A, Capusa C, Andreiana I, Mircescu G Maedica (Bucur). 2022; 17(2):436-448.

PMID: 36032600 PMC: 9375892. DOI: 10.26574/maedica.2022.17.2.436.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Spielmann M, Luporsi E, Ray-Coquard I, de Botton S, Azria D, Lasocki S . Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study. Eur J Cancer. 2011; 48(1):101-7. DOI: 10.1016/j.ejca.2011.09.011. View

Petry N, Olofin I, Hurrell R, Boy E, Wirth J, Moursi M . The Proportion of Anemia Associated with Iron Deficiency in Low, Medium, and High Human Development Index Countries: A Systematic Analysis of National Surveys. Nutrients. 2016; 8(11). PMC: 5133080. DOI: 10.3390/nu8110693. View

Beale A, Penney M, Allison M . The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis. 2005; 7(4):398-402. DOI: 10.1111/j.1463-1318.2005.00789.x. View

Baird-Gunning J, Bromley J . Correcting iron deficiency. Aust Prescr. 2016; 39(6):193-199. PMC: 5155066. DOI: 10.18773/austprescr.2016.069. View

Brownlie 4th T, Utermohlen V, Hinton P, Haas J . Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004; 79(3):437-43. DOI: 10.1093/ajcn/79.3.437. View

Ha Thi H, Hong S . Inflammasome as a Therapeutic Target for Cancer Prevention and Treatment. J Cancer Prev. 2017; 22(2):62-73. PMC: 5503217. DOI: 10.15430/JCP.2017.22.2.62. View

Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y . Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012; 23(8):1954-1962. DOI: 10.1093/annonc/mds112. View

Feinberg B, Bruno A, Haislip S, Gilmore J, Jain G, Whyte J . Hemoglobin trends and anemia treatment resulting from concomitant chemotherapy in community oncology clinics. J Oncol Pract. 2012; 8(1):18-23. PMC: 3266310. DOI: 10.1200/JOP.2011.000268. View

10.

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J . Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2012; 24(2):475-482. PMC: 3551483. DOI: 10.1093/annonc/mds338. View

11.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascon P, Glaspy J . Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(Suppl 4):iv96-iv110. DOI: 10.1093/annonc/mdx758. View

12.

Crawford J, Cella D, Cleeland C, Cremieux P, Demetri G, Sarokhan B . Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002; 95(4):888-95. DOI: 10.1002/cncr.10763. View

13.

Pedrazzoli P, Rosti G, Secondino S, Siena S . Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Cancer. 2009; 115(6):1169-73. DOI: 10.1002/cncr.24115. View

14.

Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V . Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr. 2015; 127(23-24):907-19. PMC: 4679104. DOI: 10.1007/s00508-015-0842-3. View

15.

Caro J, Salas M, Ward A, Goss G . Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91(12):2214-21. View

16.

Bruner A, Joffe A, Duggan A, Casella J, Brandt J . Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996; 348(9033):992-6. DOI: 10.1016/S0140-6736(96)02341-0. View

17.

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

18.

Verdon F, Burnand B, Stubi C, Bonard C, Graff M, Michaud A . Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003; 326(7399):1124. PMC: 156009. DOI: 10.1136/bmj.326.7399.1124. View

19.

Nairz M, Theurl I, Swirski F, Weiss G . "Pumping iron"-how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch. 2017; 469(3-4):397-418. PMC: 5362662. DOI: 10.1007/s00424-017-1944-8. View

20.

Rodgers 3rd G, Becker P, Blinder M, Cella D, Chanan-Khan A, Cleeland C . Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012; 10(5):628-53. DOI: 10.6004/jnccn.2012.0064. View